Compare RR & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RR | INDP |
|---|---|---|
| Founded | 2016 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 375.9M | 438.4M |
| IPO Year | 2023 | 2021 |
| Metric | RR | INDP |
|---|---|---|
| Price | $1.47 | $2.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.7M | 657.6K |
| Earning Date | 08-19-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,045,000.00 | N/A |
| Revenue This Year | $8.03 | N/A |
| Revenue Next Year | $22.75 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 18.99 | N/A |
| 52 Week Low | $1.30 | $0.92 |
| 52 Week High | $7.00 | $5.96 |
| Indicator | RR | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 38.13 | 48.74 |
| Support Level | $1.30 | $2.30 |
| Resistance Level | $1.79 | $2.96 |
| Average True Range (ATR) | 0.08 | 0.36 |
| MACD | -0.02 | -0.11 |
| Stochastic Oscillator | 4.84 | 19.61 |
Richtech Robotics Inc is a robotics and artificial intelligence (AI) technology company focused on developing embodied AI systems that aims to improve the efficiency and productivity of businesses. The company trains proprietary artificial intelligence models on in-house data to operate robotic systems in the real world. It designs, engineers, manufactures, and deploys next generation embodied AI systems to serve a wide range of industries, including food service, retail, industrial manufacturing, automotive, healthcare, and hospitality. The company's offerings include Commercial Robotic Products, Industrial Robotic Products and Data Services. The company generated the majority of its revenue through product revenue (i.e. outright hardware sales).
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.